Pharma Focus America

Aterian Investment Partners Completes Acquisition of Contract Pharmaceuticals Limited

Friday, June 07, 2024

Aterian Investment Partners, a private investment firm, has successfully completed its acquisition of Contract Pharmaceuticals Limited Canada (CPL), a leading North American contract development and manufacturing organization specializing in non-sterile liquid and semi-solid dosage forms.

CPL is based in Mississauga, Ontario, Canada, and is well-regarded in the industry, with long-standing relationships with 15 of the top 20 global pharmaceutical companies. The company operates FDA and Health Canada-registered facilities and serves markets in North America, the European Union, Japan, Australia, Mexico, Brazil, and the Middle East.

"We are thrilled to have closed this transaction," said the Aterian team. "With our investment in technology, personnel, and processes, CPL is ready to advance to its next growth phase, driving industry innovation and enhancing value for its customers."

"With Aterian's support, we are dedicated to innovation, growth, and customer satisfaction, further strengthening our leading position in the non-sterile liquid and topical drug products market," stated Jan Sahai, CEO of CPL. "This partnership will greatly enhance our ability to serve as a trusted partner to pharmaceutical companies globally."

Aterian, added, "CPL is our thirteenth investment in the life sciences, personal care, and nutrition sectors. We are excited to support CPL and look forward to working with the management team to continue the company’s growth."

CPL is a leading contract development and manufacturing organization that provides services in the development, manufacturing, packaging, and testing of non-sterile liquid and semi-solid pharmaceutical prescription and regulated over-the-counter products for international markets.



Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024